Menlo Park, Calif. – May 1, 2024 – ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences:
Wells Fargo Virtual Private Biotech Symposium
Format: 1×1 Investor Meetings
Date: May 6, 2024
Location: Virtual
Capital One Biotech – Life Sciences Disruptors Event
Format: Panel Discussion on “The Next Wave of mRNA and Gene Correction Therapeutics”
Date: May 14, 2024
Time: 1:45 p.m. ET
Location: New York
Virtual Piper Sandler Lung Day Post-ATS
Format: Fireside Chat
Date: May 23, 2024
Time: 12:00 – 12:25 p.m. ET
Location: Virtual
About Cystic Fibrosis
Cystic fibrosis (CF) is a progressive genetic disease that causes persistent lung infections and respiratory failure. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and impacts approximately 130,000 people worldwide. The absence or dysfunction of the CFTR protein results in a defect in airway hydration, which leads to excessive mucus buildup in the lungs. It also creates a mucociliary clearance defect, recurrent infections, inflammation, respiratory failure, and other complications. Despite advancements in CFTR modulator treatments, no available therapies exist to restore function for Class I mutations in the CFTR gene since no significant CFTR protein is produced.
About ReCode Therapeutics
ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs, tissues and cells implicated in disease, enabling improved efficacy and potency. ReCode’s lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13% of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform. ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases, including musculoskeletal, central nervous system, liver and infectious disease indications.
ReCode has been recognized by the San Francisco Business Times and Silicon Valley Business Journal as a Best Place to Work. For more information, visit www.fullcirclecf.com and follow us on LinkedIn and Instagram.
ReCode Contacts
Investors:
Anne Marie Fields
Stern IR
[email protected]
[email protected]
Media:
Erica Jefferson
Senior Vice President, Corporate Affairs
[email protected]
Tara Cooper
The Grace Group
[email protected]